To include your compound in the COVID-19 Resource Center, submit it here.

Linagliptin: Phase III data

A double-blind, placebo-controlled, international Phase III trial in 791 Type II diabetics showed that twice-daily 2.5 mg linagliptin plus 500 or

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE